Abstract
Human iPSC neuromuscular junction modelling seeks to establish an in vitro system which supports two cell types – skeletal muscle cells and motor neurons cells – in the same environment.
iPSC technology enables the generation of multiple relevant cell types, including skeletal muscle and motor neurons, from people affected by ALS patients and people not affected. In this study we derived cells from multiple ALS and unaffected iPSCs. Cells were characterized in monoculture then also in a 2D microfluidic device where they were seen to form neuromuscular junctions. Identifiable ALS relevant phenotypic differences were noted pointing towards the utility of such systems for research and drug discovery.
